ArticleJournal of thoracic disease2025
The prevalence of chronic obstructive pulmonary disease in high-altitude areas of China: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China is one of the countries with the heaviest burden of chronic obstructive pulmonary disease (COPD). In high-altitude areas of China (≥1,500 m), factors such as low oxygen levels, burning of biomass, and an aging population make the prevention and treatment of COPD more challenging. However, there is currently a lack of systematic epidemiological studies. This study aimed to assess the prevalence of COPD in high-altitude areas of China. Methods: The search was conducted in PubMed, Embase, Web of Science, Ovid, ProQuest, Scopus, The Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, Weipu, and China Biology Medicine disc (CBM) from their inception to May 17, 2025. Studies were evaluated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and registered in International Prospective Register of Systematic Reviews (PROSPERO) (Identifier: CRD420251063646). Results: A total of 6 cross-sectional studies from high-altitude areas of China (including 15,621 participants) were included. The COPD prevalence rate in high-altitude areas (≥1,500 m) of China was 10% [95% confidence interval (CI): 7-14%; P<0.001]. Subgroup analysis showed that the prevalence rate in people aged ≥50 years was significantly higher than that in those aged 40-49 years (17% Conclusions: The prevalence of COPD in high-altitude areas of China is 10%, which is closely related to aging and smoking. It is necessary to promote clean energy and strengthen health education for targeted intervention. In the future, priority should be given to conducting age-standardized estimates and multi-center studies to verify the results and provide a basis for COPD prevention and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.